



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/29/05 Signature: Kathryn Lugo  
(Kathryn Lugo)

Docket No.: AREX-P01-015  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
*Eng et al.*

Application No.: 10/510,361

Confirmation No.: 6278

Filed: June 20, 2005

Art Unit: 1614

For: BINDING AGENTS AND THEIR USE IN  
TARGETING TUMOR CELLS

Examiner: Not Yet Assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant submits herewith copies of foreign patent and non-patent documents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent,

publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. AREX-P01-015. A duplicate copy of this paper is enclosed.

Dated: November 29, 2005

Respectfully submitted,

By   
Gloria Fuentes

Registration No.: 47,580  
ROPES & GRAY LLP  
One International Place  
Boston, Massachusetts 02110-2624  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/510,361
				Filing Date	June 20, 2005
				First Named Inventor	Hubert Eng
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	AREX-P01-015

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BC	WO 98/57661	12-23-1998	Altarex Corp.		
	BD	WO 02/076384 A2	10-03-2002	Altarex Corp.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	CH	AltaRex Corp. "AltaRex Corp. (AXO) Reports Favorable OvaRex <sup>(R)</sup> Phase II Trial Results", Biospace, 1/3/2001, pp 1.		
	CI	SCHULTES, et al., "Induction of tumor- and CA125-specific T cell responses in patients (pts) with epithelial ovarian cancer (EOC) treated with OvaRex <sup>(R)</sup> ", Proceedings of the American Association for Cancer Research, Volume 43, March 2002, pp. 144 (Abstract only).		
	CJ	NOUJAIM, A. et al., Induction of CA125-Specific B and T Cell Responses in Patients Injected with Mab-B43.13 - Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo, Cancer Biotherapy & Radiopharmaceuticals, Volume 16, Number 3, 2001, pp. 187-203.		
	CK	SCHULTES, B. et al., "Antibody-antigen immune complexes allow for efficient MHC class I and II-restricted antigen presentation and maturation of dendritic cells: a novel strategy for cancer immunotherapy", Proceedings of the 92 <sup>nd</sup> Annual Meeting of The American Association for Cancer Research, New Orleans, LA, March 24-28, 2001, Proceedings of the Annual Meeting of The American Association for Cancer Research, Philadelphia, PA: ACCR, US, Vol. 42, March 24, 2001, pp. 276 (Abstract only)		
	CL	EHLEN, T., et al., "Induction of tumor protective immunity utilizing the CA125 specific monoclonal, OvaRex, Mab-B43.13, in a cohort of patients with advanced recurrent ovarian cancer", Thirty-second Annual Meeting of the Society of Gynecologic Oncologists, Nashville, Tennessee, March 3-7, 2001 (Abstract only)		
	CM	BRUKNER, I. et al., OvaRex AltaRex, IDrugs: The Investigational Drugs Journal, vol. 4, no. 4, April 2001, pp. 457-462.		
	CN	MOINGEON, P., "Cancer vaccines", Vaccine, 19 (2001) pp. 1305-1326.		
	CO	SCHULTES, B. et al., "Immunotherapy of Human Ovarian Carcinoma with OVAREX <sup>TM</sup> Mab-B43.13 in a Human-PBL-SCID/BG Mouse Model", Hybridoma, Vol. 18, No. 1, 1999, pp. 47-55.		
	CP	MADIYALAKAN, R. et al., "Antidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/510,361
				Filing Date	June 20, 2005
				First Named Inventor	Hubert Eng
				Art Unit	1614
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	AREX-P01-015
Sheet	2	of	2		

		Administration of Anti-CA125 Murine Monoclonal Antibody B43.13", Hybridoma, Vol. 14, No. 2, 1995, pp. 199-203.	
	CQ	OLTROGGE, J.B. et al., "Generation of human monoclonal anti-idiotypic antibodies with specificity to the murine monoclonal anti-CA 125 antibody B43.13", The International Journal of Biological Markers, 1996 Oct-Dec, Vol. 11, No. 4, October 1996, pp. 211-215.	
	CR	COCCIA, M. et al., "High Titer, Prostate Specific Antigen-Specific Human IgG Production by hu-PBL-SCID Mice Immunized with Antigen-Mouse IgG2a Complex-Pulsed Autologous Dendritic Cells", Journal of Immunology, Vol. 161, No. 10, November 15, 1998, pp. 5772-5780.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/92 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/510,361

Attorney Docket No.: AREX-P01-015

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on November 29, 2005  
Date

*Kathryn Lugo*

Signature

*KATHRYN LUGO*

Typed or printed name of person signing Certificate

Registration Number, if applicable

212-596-9000  
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental Information Disclosure Statement (2 pages in duplicate)  
(Total: 4 pages)  
SB/08 (2 pages) (13 References)  
Copy of references BC-BD and CH-CR  
Return receipt postcard